A nurse prepares to inject a volunteer taking part in an Iranian coronavirus disease (COVID-19) vaccine trial in Tehran, Iran December 29, 2020. (Reuters)

By Pouyan Khoshhal

February 8, 2021

Iran is due to start coronavirus vaccinations tomorrow on Tuesday, February 9, using the first shipment of the Russian Sputnik V it received last week. Health Minister Saeed Namaki also reaffirmed that health workers in ICUs would take priority, followed by other frontline mecial staff and high-risk groups including the elderly.

Iran received 20,000 doses of the Russian vaccine last Thursday: enough to vaccinate 10,000 people. The first inoculations are therefore largely symbolic and will be taking place in Tehran, with health officials stating they believe up to 1,000 people could receive the jab.

Over the past few weeks Iranian officials have proffered different start dates for so-called general vaccination, ranging from early spring to early summer.

Clinical Trials of Iran’s Second Homegrown Vaccine Under Way

Iran has unveiled its second domestically-developed Covid-19 vaccine, based on a recombinant protein that can be injected or inhaled. The vaccine, called Cov-Pars, is being made by the Razi Vaccine and Serum Research Institute, Iran’s oldest vaccine development center. It now has received a permit from the Health Ministry to start clinical trials on humans.

According to Kianoush Jahanpour, a spokesman for Iran’s Food and Drug Administration, the vaccine will be tested on 130 volunteers in its first phase of clinical trials. He added that Razi Cov-Pars is an mRNA (messenger RNA) vaccine that reconstructs a harmless piece of the virus’ spike protein.

The vaccine has been developed under the supervision of the Health Ministry and in compliance with standards set by the World Health Organization (WHO), said Saeed Namaki. He added that this product utilizes a combination of an “inhaled dose” and an injection to stimulate the immune system, adding that it has “few side effects” and can be “reconfigured” in the event of virus mutations.

At the unveiling ceremony, Namaki also told the audience that the vaccine could stop the recipient from transmitting the virus to others. Agriculture Minister Kazem Khavazi said animal trials of the vaccine had got under way more than nine months ago and tests were conducted on about 500 animals. “Testing on 25 monkeys was also an unprecedented record and a big undertaking. during which a large number of the Razi institute’s staff contracted the virus,” he said.

Simultaneously, Namaki also reported that Iran’s first vaccine, CovIran-Barekat, has now completed its first phase of human trials – during which the vaccine was administered to just 56 volunteers, including a handful of officials. These trials began in late December and officials have said the initial results will be published in less than a month from now. Hojjat Niki Maleki, head of media for Setad, the parastatal conglomerate controlled by the Supreme Leader that owns Barekat, said two Arab countries have formally asked to purchase the vaccine. He did not name these countries.

Iran Wire

About Track Persia

Track PersiaTrack Persia is a Platform run by dedicated analysts who spend much of their time researching the Middle East, in due process we fall upon many indications of growing expansionary ambitions on the part of Iran in the MENA region and the wider Islamic world. These ambitions commonly increase tensions and undermine stability.